Business
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
LOS ANGELES, January 12, 2026--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced corporate, financial, and pipeline updates in advance of its participation at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco. Throughout the conference, Turn Therapeutics will participate in investor and partner meetings to
About this update from Turn Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/ec3c110d9fd1d6e79f5b0f7a0eeec577"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DnC7EicjVILa5KwlHFK.PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ec3c110d9fd1d6e79f5b0f7a0eeec577","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_mdbwuPY8PBXMlAmQhj8lw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/ec3c110d9fd1d6e79f5b0f7a0eeec577","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026","length":142,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":142,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Appointment of Martin Dewhurst, a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directors","length":122,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":122,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expansion of intranasal vaccine pipeline to include intranasal Influenza candidate that may stimulate systemic immunity via targeted intranasal exposure without adjuvants or potentially harmful additives","length":203,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":203,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Progress on commercial partnerships with expected revenue generation in 2026 in advanced wound care market","length":106,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":106,"olType":false},{"type":"text","content":"LOS ANGELES, January 12, 2026--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced corporate, financial, and pipeline updates in advance of its participation at the 2026 J.P. Morgan Healthcare Conference, taking place ...